Morgan Stanley Maintains Equal-Weight on Haemonetics, Raises Price Target to $70

Morgan Stanley analyst Drew Ranieri maintains Haemonetics (NYSE:HAE) with a Equal-Weight and raises the price target from $60 to $70.

Morgan Stanley analyst Drew Ranieri maintains Haemonetics (NYSE:HAE) with a Equal-Weight and raises the price target from $60 to $70.

Total
0
Shares
Related Posts